Chikungunya, RSV, Universal Dengue, Flu-COVID Combo & More | June 2025 Vaccine Breakthroughs 🌍💉đź§
In this week’s edition of Vaccine Research Updates, we spotlight powerful advances driving the future of global immunization—from pediatric breakthroughs to next-gen pandemic preparedness. These are the stories reshaping the vaccine landscape:
🦟 Valneva’s pediatric chikungunya vaccine shows a 96.5 percent seroresponse rate in children aged 1–11—clearing the path for Phase 3 in early 2026.
🧪 ImmunoPrecise’s AI platform, LENSai, discovers a structural epitope shared by all four dengue virus serotypes—bringing us closer to a universal dengue vaccine.
👶 Merck’s Clesrovimab gains FDA approval for infant RSV protection—reducing hospitalizations by more than 84 percent in clinical trials.
🦠Oxford’s Nipah virus vaccine earns EMA PRIME status—accelerating development against a pathogen with fatality rates up to 85 percent.
🌍 Osivax completes Phase 2a trial of its broad-spectrum flu vaccine OVX836—targeting long-term immunity against influenza A.
💉 Novavax reports strong Phase 3 data for its flu and COVID-19 combo vaccine—over 98 percent of adverse events were mild or moderate.
🧒 Bavarian Nordic launches a global Phase 3 pediatric trial of its CHIKV VLP vaccine—aiming to expand protection to children aged 2–11.
📢 Stay Ahead in Vaccine Research!
âś… Like, share, and subscribe for weekly updates on vaccine research
#VaccineResearch #ChikungunyaVaccine #RSVPrevention #UniversalDengueVaccine #NipahVirus #OxfordVaccine #FluCOVIDCombo #Novavax #Osivax #PediatricVaccines #LucidQuest #LQVentures #ClinicalTrials #InfectiousDiseases #BiotechNews #PublicHealth #FDAApproval #GlobalHealth #AIinHealthcare #Merck #CEPI #EMA #VaccineDevelopment
Â